Schultz H - Search Results

1

ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations.

Schultz H, Csernok E, Herlyn K, Reichel PH, Moosig F, Cornely OA, Fagerhol MK, Gross WL. Schultz H, et al. Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S117-20. Clin Exp Rheumatol. 2003. PMID: 14740437

2

Bactericidal/permeability-increasing protein is expressed by human dermal fibroblasts and upregulated by interleukin 4.

Reichel PH, Seemann C, Csernok E, Schröder JM, Müller A, Gross WL, Schultz H. Reichel PH, et al. Among authors: schultz h. Clin Diagn Lab Immunol. 2003 May;10(3):473-5. doi: 10.1128/cdli.10.3.473-475.2003. Clin Diagn Lab Immunol. 2003. PMID: 12738651 Free PMC article.

3

BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.

Schultz H, Schinke S, Mosler K, Herlyn K, Schuster A, Gross WL. Schultz H, et al. Pediatr Pulmonol. 2004 Feb;37(2):158-64. doi: 10.1002/ppul.10416. Pediatr Pulmonol. 2004. PMID: 14730661

4

Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.

Schinke S, Fellermann K, Herlyn K, Reichel PH, Fundke R, Stange EF, Gross WL, Schultz H. Schinke S, et al. Among authors: schultz h. Inflamm Bowel Dis. 2004 Nov;10(6):763-70. doi: 10.1097/00054725-200411000-00011. Inflamm Bowel Dis. 2004. PMID: 15626895

5

Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA.

Schultz H, Csernok E, Johnston TW, Lockwood CM, Gross WL. Schultz H, et al. J Immunol Methods. 1997 Jul 14;205(2):127-33. doi: 10.1016/s0022-1759(97)00067-7. J Immunol Methods. 1997. PMID: 9294593

6

[Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].

Schnabel A, Csernok E, Schultz H, Stoffel M, Herzberg C, Carroll SF, Gross WL. Schnabel A, et al. Among authors: schultz h. Med Klin (Munich). 1997 Jul 15;92(7):389-93. doi: 10.1007/BF03042568. Med Klin (Munich). 1997. PMID: 9324622 German.

7

Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.

Schultz H, Csernok E, Schuster A, Schmitz TS, Ernst M, Gross WL. Schultz H, et al. Pediatr Allergy Immunol. 2000 May;11(2):64-70. doi: 10.1034/j.1399-3038.2000.00069.x. Pediatr Allergy Immunol. 2000. PMID: 10893006

8

BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognise exclusively the C-terminal part of the BPI molecule.

Schultz H, Csernok E, Nikkari S, Toivanen P, Toivanen A, Gross WL. Schultz H, et al. Scand J Rheumatol. 2000;29(4):226-31. doi: 10.1080/030097400750041361. Scand J Rheumatol. 2000. PMID: 11028843

9

The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.

Schultz H, Weiss J, Carroll SF, Gross WL. Schultz H, et al. J Leukoc Biol. 2001 Apr;69(4):505-12. J Leukoc Biol. 2001. PMID: 11310835 Review.

10

BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.

Schultz H, Schinke S, Weiss J, Cerundolo V, Gross WL, Gadola S. Schultz H, et al. Clin Exp Immunol. 2003 Aug;133(2):252-9. doi: 10.1046/j.1365-2249.2003.02197.x. Clin Exp Immunol. 2003. PMID: 12869032 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

610 results

Search Page